Design, synthesis and anti-tumor evaluation of 1,2,4-triazol-3-one derivatives and pyridazinone derivatives as novel CXCR2 antagonists
作者:Xun Zhang、Jingyi Luo、Qinyuan Li、Qilei Xin、Lizhen Ye、Qingyun Zhu、Zhichao Shi、Feng Zhan、Bizhu Chu、Zijian Liu、Yuyang Jiang
DOI:10.1016/j.ejmech.2021.113812
日期:2021.12
therapy. CXCR2 antagonists could block CXCLs/CXCR2 axis, and are widely used in regulating immune cell migration, tumor metastasis, apoptosis and angiogenesis. Herein, two series of new CXCR2 small-molecule inhibitors, including 1,2,4-triazol-3-one derivatives 1–11 and pyridazinone derivatives 12–22 were designed and synthesized based on the proof-to-concept. The pyridazinone derivative 18 exhibited
趋化因子受体 2 (CXCR2) 是含有谷氨酸-亮氨酸-精氨酸序列的趋化因子 CXCs (ELR + CXCs) 的受体。近年来,CXCR2靶向治疗策略在癌症治疗中取得了长足的进步。CXCR2拮抗剂可阻断CXCLs/CXCR2轴,广泛用于调节免疫细胞迁移、肿瘤转移、细胞凋亡和血管生成。在此,基于概念验证设计和合成了两个系列的新型CXCR2小分子抑制剂,包括 1,2,4-triazol-3-one 衍生物1-11和哒嗪酮衍生物12-22 。哒嗪酮衍生物18表现出良好的 CXCR2 拮抗活性(10 μM 时为 69.4 ± 10.5 %Inh),并在 MDA-MB-231 细胞中表现出显着的抗癌转移活性,在 HUVEC 中表现出显着的抗血管生成活性。此外,值得注意的是,18在MDA-MB-231细胞的抗增殖试验中与索拉非尼表现出明显的协同作用。此外,18显示 MDA-MB-231 细胞中 PI3K